Joslin Diabetes Center, 1 Joslin Pl, Boston, MA, 02215, USA.
Curr Diab Rep. 2018 Jun 16;18(8):50. doi: 10.1007/s11892-018-1028-y.
There is considerable interest in using macroencapsulation devices as a delivery strategy for transplanting insulin-producing cells. This review aims to summarize recent advances, to highlight remaining challenges, and to provide recommendations for the field.
A variety of new device designs have been reported to improve biocompatibility and to provide protection for islet/beta cells from immune destruction while allowing continuous secretion of insulin. Some of these new approaches are in clinical trials, but more research is needed to determine how sufficient beta-cell mass can be transplanted in a clinically applicable device size, and that insulin is secreted with kinetics that will safely provide adequate controls of glucose levels. Macroencapsulation is a potential solution to transplant beta cells without immunosuppression in diabetes patients, but new strategies must be developed to show that this approach is feasible.
人们对使用宏观封装设备作为移植胰岛素分泌细胞的递送策略非常感兴趣。本综述旨在总结最新进展，突出仍存在的挑战，并为该领域提供建议。
已报道了各种新的设备设计，以改善生物相容性，并为胰岛/β细胞提供保护，使其免受免疫破坏，同时允许胰岛素持续分泌。其中一些新方法正在临床试验中，但需要进一步研究，以确定如何在临床适用的设备尺寸中移植足够的β细胞质量，并且胰岛素的分泌动力学能够安全地提供足够的血糖控制。宏观封装是一种在糖尿病患者中移植β细胞而无需免疫抑制的潜在解决方案，但必须开发新策略来证明这种方法是可行的。
